Tolerability and Immunogenicity Study of FLUVAL AB Influenza Vaccine (trivalent, seasonal, active ingredient content: 15 μgHA/strain/0.5 mL) for the Use in the Season 2013/2014 in Adults and Elderly Subjects

Trial Profile

Tolerability and Immunogenicity Study of FLUVAL AB Influenza Vaccine (trivalent, seasonal, active ingredient content: 15 μgHA/strain/0.5 mL) for the Use in the Season 2013/2014 in Adults and Elderly Subjects

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Sep 2013

At a glance

  • Drugs Influenza virus vaccine (Primary)
  • Indications Influenza virus infections
  • Focus Pharmacodynamics
  • Sponsors Omninvest
  • Most Recent Events

    • 04 Sep 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top